Literature DB >> 8228822

A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.

N Yuki1, T Taki, F Inagaki, T Kasama, M Takahashi, K Saito, S Handa, T Miyatake.   

Abstract

There is a strong association between Guillain-Barré syndrome (GBS) and Penner's serotype 19 (PEN 19) of Campylobacter jejuni. Sera from patients with GBS after C. jejuni infection have autoantibodies to GM1 ganglioside in the acute phase of the illness. Our previous work has suggested that GBS results from an immune response to cross-reactive antigen between lipopolysaccharide (LPS) of the Gram-negative bacterium and membrane components of peripheral nerves. To clarify the pathogenesis of GBS, we have investigated whether GM1-oligosaccharide structure is present in the LPS of C. jejuni (PEN 19) that was isolated from a GBS patient. After extraction of the LPS, the LPS showing the binding activity of cholera toxin, that specifically recognizes the GM1-oligosaccharide was purified by a silica bead column chromatography. Gas-liquid chromatography-mass spectrometric analysis has shown that the purified LPS contained Gal, GalNAc, and NeuAc, which are sugar components of GM1 ganglioside. 1H NMR methods [Carr-Purcell-Meiboom-Gill (CPMG), total correlation spectroscopy (TOCSY), and nuclear Overhauser effect spectroscopy (NOESY)] have revealed that the oligosaccharide structure [Gal beta 1-3 GalNAc beta 1-4(NeuAc alpha 2-3)Gal beta] protrude from the LPS core. This terminal structure [Gal beta 1-3GalNAc beta 1-4(NeuAc alpha 2-3)Gal beta] is identical to the terminal tetrasaccharide of the GM1 ganglioside. This is the first study to demonstrate the existence of molecular mimicry between nerve tissue and the infectious agent that elicits GBS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228822      PMCID: PMC2191246          DOI: 10.1084/jem.178.5.1771

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

Review 1.  The Guillain-Barré syndrome.

Authors:  A H Ropper
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Guillain-Barré syndrome and parenteral gangliosides.

Authors: 
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

3.  HLA-B35 and acute axonal polyneuropathy following Campylobacter infection.

Authors:  N Yuki; S Sato; T Itoh; T Miyatake
Journal:  Neurology       Date:  1991-10       Impact factor: 9.910

4.  Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GD1b from a patient with motor neuron disease.

Authors:  M Schluep; A J Steck
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

5.  Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide.

Authors:  G O Aspinall; A G McDonald; T S Raju; H Pang; L A Kurjanczyk; J L Penner; A P Moran
Journal:  Eur J Biochem       Date:  1993-05-01

6.  A rapid and sensitive method for the analysis of carbohydrate components in glycoproteins using gas-liquid chromatography.

Authors:  M F Chaplin
Journal:  Anal Biochem       Date:  1982-07-01       Impact factor: 3.365

7.  Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens.

Authors:  J L Penner; J N Hennessy
Journal:  J Clin Microbiol       Date:  1980-12       Impact factor: 5.948

8.  Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier.

Authors:  F P Thomas; W Trojaborg; C Nagy; M Santoro; S A Sadiq; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides.

Authors:  G O Aspinall; A G McDonald; T S Raju; H Pang; S D Mills; L A Kurjanczyk; J L Penner
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

10.  A prospective study of acute idiopathic neuropathy. II. Antecedent events.

Authors:  J B Winer; R A Hughes; M J Anderson; D M Jones; H Kangro; R P Watkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

View more
  92 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  Specificity of antiglycolipid antibodies.

Authors:  N Baumann
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 3.  Relationship between autoantibody specificities and peripheral nervous system involvements.

Authors:  M O Jauberteau-Marchan
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 4.  Immunogenicity of glycolipids.

Authors:  J Portoukalian
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

5.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

7.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

8.  Guillain-Barré syndrome associated with IgM anti-GM1 antibody following Campylobacter jejuni enteritis.

Authors:  K Sugita; M Ishii; J Takanashi; H Niimi; N Yuki
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

Review 9.  Guillain-Barré syndrome. Clinical manifestations and directions for treatment.

Authors:  J Rees
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function.

Authors:  Roland W M Bullens; Graham M O'Hanlon; Eric Wagner; Peter C Molenaar; Keiko Furukawa; Koichi Furukawa; Jaap J Plomp; Hugh J Willison
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.